Prognostic role of H3K27M mutation, histone H3K27 methylation status, and EZH2 expression in diffuse spinal cord gliomas

Abstract

The objective of this study is to clarify clinical significance of the H3F3A K27M mutation (H3K27M) and analyze the correlation between H3K27M, H3K27me3 status, and EZH2 expression and prognosis in spinal cord gliomas. Patients with spinal cord diffuse glioma regardless of World Health Organization (WHO) grade underwent genetic analysis for H3F3A, HIST1H3B, TERT promoter, IDH1/2, and BRAF. H3K27me3 status and EZH2 expression were analyzed through immunohistochemistry. Thereafter, the association between H3K27M, H3K27me3 status, and EZH2 expression and prognosis was retrospectively analyzed using the log-rank test. A total of 26 cases, 5 with WHO grade 4, 9 with grade 3, and 12 with grade 2 glioma, were analyzed. Although WHO grade 2 cases tended to present favorable overall survival, the difference was not statistically significant. H3K27M, which was detected in four grade 4 cases (80%) and three grade 3 cases (33%), was not associated with prognosis among grade 3 and 4 cases. Among WHO grade 2–4 cases, the combination of retained H3K27me3 and negative EZH2 expression was correlated with favorable overall survival (p = 0.03). The combination of H3K27me3 status and EZH2 expression was considered as a potential prognostic marker in WHO grade 2–4 diffuse spinal cord gliomas.

This is a preview of subscription content, log in to check access.

Fig. 1.
Fig. 2
Fig. 3
Fig. 4

Abbreviations

DMG:

Diffuse midline glioma

FFPE:

Formalin-fixed paraffin embedded

GBM:

Glioblastoma

H3K27M:

Histone H3K27M mutation

HE:

Hematoxylin and eosin

IHC:

Immunohistochemical staining

KDM6A:

Lysine-specific demethylase 6A

MGMT:

Methylguanine methyltransferase

MRI:

Magnetic resonance imaging

OS:

Overall survival

PRC2:

Polycomb repressive complex 2

TMZ:

Temozolomide

WHO:

World Health Organization

References

  1. 1.

    Schwartzentruber J, Korshunov A, Liu XY et al (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482:226–231

    Article  CAS  Google Scholar 

  2. 2.

    Wu G, Broniscer A, McEachron TA et al (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44:251–253

    Article  CAS  Google Scholar 

  3. 3.

    Aihara K, Mukasa A, Gotoh K et al (2014) H3F3A K27M mutations in thalamic gliomas from young adult patients. Neuro-oncology 16:140–146

    Article  CAS  Google Scholar 

  4. 4.

    Gessi M, Gielen GH, Dreschmann V et al (2015) High frequency of H3F3A (K27M) mutations characterizes pediatric and adult high-grade gliomas of the spinal cord. Acta Neuropathol 130:435–437

    Article  Google Scholar 

  5. 5.

    Shankar GM, Lelic N, Gill CM et al (2016) BRAF alteration status and the histone H3F3A gene K27M mutation segregate spinal cord astrocytoma histology. Acta Neuropathol 131:147–150

    Article  Google Scholar 

  6. 6.

    Hawkins C, Ellison DW, Sturm D (2016) Diffusse midline glioma, H3 K27M-mutant. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO Classification of tumours of the central nervous systemedn. Int Agency Res Cancer, Lyon, pp 57–59

    Google Scholar 

  7. 7.

    Ryu SJ, Kim JY, Kim KH et al (2016) A retrospective observational study on the treatment outcomes of 26 patients with spinal cord astrocytoma including two cases of malignant transformation. Eur Spine J 25:4067–4079

    Article  Google Scholar 

  8. 8.

    Solomon DA, Wood MD, Tihan T et al (2015) Diffuse midline gliomas with histone H3–K27M mutation: a series of 47 cases assessing the spectrum of morphologic variation and associated genetic alterations. Brain Pathol. https://doi.org/10.1111/bpa.12336

    Article  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Bender S, Tang Y, Lindroth AM et al (2013) Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell 24:660–672

    Article  CAS  Google Scholar 

  10. 10.

    Venneti S, Garimella MT, Sullivan LM et al (2013) Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas. Brain Pathol 23:558–564

    Article  CAS  Google Scholar 

  11. 11.

    Mohammad F, Weissmann S, Leblanc B et al (2017) EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. Nat Med 23:483–492

    Article  CAS  Google Scholar 

  12. 12.

    Lewis PW, Muller MM, Koletsky MS et al (2013) Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 340:857–861

    Article  CAS  Google Scholar 

  13. 13.

    Lee W, Teckie S, Wiesner T et al (2014) PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet 46:1227–1232

    Article  CAS  Google Scholar 

  14. 14.

    Cleven AH, Sannaa GA, Briaire-de Bruijn I et al (2016) Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Mod Pathol 29:582–590

    Article  CAS  Google Scholar 

  15. 15.

    Panwalkar P, Clark J, Ramaswamy V et al (2017) Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. Acta Neuropathol 134:705–714

    Article  CAS  Google Scholar 

  16. 16.

    Karlowee V, Amatya VJ, Takayasu T et al (2019) Immunostaining of increased expression of enhancer of zeste homolog 2 (EZH2) in diffuse midline glioma H3K27M-mutant patients with poor survival. Pathobiology 86:152–161

    Article  CAS  Google Scholar 

  17. 17.

    Suva ML, Riggi N, Janiszewska M et al (2009) EZH2 is essential for glioblastoma cancer stem cell maintenance. Can Res 69:9211–9218

    Article  CAS  Google Scholar 

  18. 18.

    Otsuka H, Kohashi K, Yoshimoto M et al (2018) Immunohistochemical evaluation of H3K27 trimethylation in malignant peripheral nerve sheath tumors. Pathol Res Pract 214:417–425

    Article  CAS  Google Scholar 

  19. 19.

    Wu Z, Wang Q, Wang L et al (2013) Combined aberrant expression of Bmi1 and EZH2 is predictive of poor prognosis in glioma patients. J Neurol Sci 335:191–196

    Article  CAS  Google Scholar 

  20. 20.

    Alvi MA, Ida CM, Paolini MA et al (2019) Spinal cord high-grade infiltrating gliomas in adults: clinico-pathological and molecular evaluation. Mod Pathol. https://doi.org/10.1038/s41379-019-0271-3

    Article  PubMed  Google Scholar 

  21. 21.

    Yi S, Choi S, Shin DA et al (2019) Impact of H3.3 K27M mutation on prognosis and survival of grade IV spinal cord glioma on the basis of New 2016 World Health Organization Classification of the Central Nervous System. Neurosurgery 84:1072–1081

    Article  Google Scholar 

  22. 22.

    Wang L, Li Z, Zhang M et al (2018) H3 K27M-mutant diffuse midline gliomas in different anatomical locations. Hum Pathol 78:89–96

    Article  CAS  Google Scholar 

  23. 23.

    Khuong-Quang DA, Buczkowicz P, Rakopoulos P et al (2012) K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 124:439–447

    Article  CAS  Google Scholar 

  24. 24.

    Buczkowicz P, Bartels U, Bouffet E et al (2014) Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications. Acta Neuropathol 128:573–581

    Article  CAS  Google Scholar 

  25. 25.

    Castel D, Philippe C, Calmon R et al (2015) Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol 130:815–827

    Article  CAS  Google Scholar 

  26. 26.

    Liu Y, Zhang Y, Hua W et al (2019) Clinical and molecular characteristics of thalamic gliomas: retrospective report of 26 cases. World Neurosurg. https://doi.org/10.1016/j.wneu.2019.03.061

    Article  PubMed  PubMed Central  Google Scholar 

  27. 27.

    Abe H, Natsumeda M, Okada M et al (2019) MGMT expression contributes to temozolomide resistance in H3K27M-mutant diffuse midline gliomas. Front Oncol 9:1568

    Article  Google Scholar 

  28. 28.

    Chai RC, Zhang YW, Liu YQ et al (2020) The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation. Acta Neuropathol Commun 8:40

    Article  CAS  Google Scholar 

  29. 29.

    von Bueren AO, Karremann M, Gielen GH et al (2018) A suggestion to introduce the diagnosis of “diffuse midline glioma of the pons, H3 K27 wildtype (WHO grade IV)”. Acta Neuropathol 136:171–173

    Article  CAS  Google Scholar 

  30. 30.

    Huynh JL, Casaccia P (2013) Epigenetic mechanisms in multiple sclerosis: implications for pathogenesis and treatment. Lancet Neurol 12:195–206

    Article  CAS  Google Scholar 

  31. 31.

    Ler LD, Ghosh S, Chai X et al. (2017) Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2. Sci Transl Med 9

  32. 32.

    Yamagishi M, Hori M, Fujikawa D et al (2019) Targeting excessive EZH1 and EZH2 activities for abnormal histone methylation and transcription network in malignant lymphomas. Cell Rep 29(2321–2337):e2327

    Google Scholar 

  33. 33.

    Hashizume R, Andor N, Ihara Y et al (2014) Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat Med 20:1394–1396

    Article  CAS  Google Scholar 

  34. 34.

    Piunti A, Hashizume R, Morgan MA et al (2017) Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Nat Med 23:493–500

    Article  CAS  Google Scholar 

  35. 35.

    Mount CW, Majzner RG, Sundaresh S et al (2018) Potent antitumor efficacy of anti-GD2 CAR T cells in H3–K27M(+) diffuse midline gliomas. Nat Med 24:572–579

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Enago (www.enago.jp) for the English review.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Shigeru Yamaguchi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ishi, Y., Takamiya, S., Seki, T. et al. Prognostic role of H3K27M mutation, histone H3K27 methylation status, and EZH2 expression in diffuse spinal cord gliomas. Brain Tumor Pathol 37, 81–88 (2020). https://doi.org/10.1007/s10014-020-00369-9

Download citation

Keywords

  • Spinal cord
  • Glioma
  • H3F3A
  • H3K27me3
  • EZH2